Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
about
Targeting angiogenesis in gynecologic cancersPhase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysisPrognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian CancerEmpirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform.Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancerCited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.Current status of bevacizumab in advanced ovarian cancerAnalysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells.Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.Emerging therapies: angiogenesis inhibitors for ovarian cancer.A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.Novel antiangiogenic therapies in ovarian cancer.Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety.Trial watch: Monoclonal antibodies in cancer therapy
P2860
Q26824766-AE684C12-CF83-4C2B-85BD-534241CACE99Q35064031-03E99B71-1EA4-45CA-AD8B-8876A8361668Q35533363-FEA8CC2B-8DD5-40D1-AFA5-AAFAA298A927Q35931270-E29EEF6A-DCFD-4FFA-B1A2-D1DCDF12B91FQ36011137-4A61A0E5-8259-4001-A2CF-8A7D7193F9CAQ36564821-304AB596-3BE1-4827-86E7-0EF2CBDF6E9AQ36742449-9D507DA5-F51D-45C1-824B-1007288B1811Q37029841-54FA818C-6F24-43EB-AFDF-EB97603DBDD1Q37048186-C872BDB0-F48D-40A6-A101-C82FEDD8462DQ37636771-22864A93-CAA2-43BE-93CE-37FEDD40CC89Q37679904-C7E7E2FB-BE70-4994-87C5-95DA3E8B2D41Q38081238-45898FDD-ACF4-47AD-B062-B1194DB6857AQ38151193-02AE69CA-5373-41B3-8F0D-812C098610B4Q38497958-37817865-BF52-4E4C-8182-872CF7CD389FQ47118132-1173FBD2-1901-4287-ABEC-BF5AEFCB20E0Q47424260-B4971168-C354-4818-AEC2-4345FEC5E55DQ47603079-9221EC22-F8C7-4F4D-825F-53C96FC3CE86Q56932681-B9460796-3C1F-4711-B087-099165374504
P2860
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase II study of intraperiton ...... III epithelial ovarian cancer.
@ast
Phase II study of intraperiton ...... III epithelial ovarian cancer.
@en
type
label
Phase II study of intraperiton ...... III epithelial ovarian cancer.
@ast
Phase II study of intraperiton ...... III epithelial ovarian cancer.
@en
prefLabel
Phase II study of intraperiton ...... III epithelial ovarian cancer.
@ast
Phase II study of intraperiton ...... III epithelial ovarian cancer.
@en
P2093
P2860
P356
P1476
Phase II study of intraperiton ...... III epithelial ovarian cancer.
@en
P2093
Alexia Iasonos
Carol A Aghajanian
David R Spriggs
Diana M Grabon
Howard Thaler
Katherine M Bell-McGuinn
Martee L Hensley
Paul J Sabbatini
Sandra D Pezzulli
Scott R Gerst
P2860
P304
P356
10.1200/JCO.2011.36.1352
P407
P50
P577
2011-11-07T00:00:00Z